Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29931942 | 1.00 | GRM2 (0.32) | GRM2BPTFC5AR1PREPTRPA1 | |
| SCHEMBL23536005 | 0.86 | MEN1 (0.33) | BPTFC5AR1TRPA1 | |
| SCHEMBL23536178 | 0.86 | MEN1 (0.33) | BPTFC5AR1TRPA1 | |
| SCHEMBL23536259 | 0.82 | ALDH1A1 (0.36) | GRM2 | |
| SCHEMBL29931820 | 0.82 | ALDH1A1 (0.36) | GRM2 | |
| SCHEMBL23536073 | 0.77 | BPTF (0.34) | GRM2BPTFTRPA1 | |
| SCHEMBL29932313 | 0.77 | BPTF (0.34) | GRM2BPTFTRPA1 | |
| SCHEMBL14804508 | 0.75 | BPTF (0.38) | BPTFPREP | |
| SCHEMBL23535973 | 0.74 | CYP2A13 (0.34) | BPTF | |
| SCHEMBL23536058 | 0.74 | CYP2A13 (0.34) | BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | GRM2 190/4885BPTF 4279/4885C5AR1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.